Efforts to expand immunotherapy benefit in gastrointestinal cancers focus on identifying subsets that may be more responsive to checkpoint blockade, developing combination strategies to overcome immunotherapy resistance, and leveraging the tumor microenvironment to enhance immune responsiveness in traditionally non-immunogenic malignancies.
No takes yet. Share an insight, caveat, or question.
Pabon et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: